Clinical Trials
33 trialsNCT03132922 2026-06-04
MAGE-A4ᶜ¹º³²T for Multi-Tumor
USWM, LLC (dba US WorldMeds)
Phase 1 Active not recruiting
NCT07613723 2026-05-29
A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies
Zelluna Immunotherapy AS
Phase 1 Recruiting
NCT05492682 2026-05-12
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Valo Therapeutics Oy
Phase 1 Recruiting
NCT03967223 2026-04-17
IGNYTE-ESO
USWM, LLC (dba US WorldMeds)
Phase 2 Active not recruiting
NCT03478462 2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1 Active not recruiting
NCT03016819 2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3 Recruiting
NCT07174427 2026-02-18
Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma
Takara Bio Inc.
Phase 3 Recruiting
NCT05642455 2026-02-09
SPEARHEAD-3 Pediatric Study
USWM, LLC (dba US WorldMeds)
Phase 1/2 Recruiting
NCT04044768 2026-02-06
Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
USWM, LLC (dba US WorldMeds)
Phase 2 Active not recruiting
NCT06946225 2026-01-08
ACTengine® IMA203 Combined With mRNA-4203
Immatics US, Inc.
Phase 1 Recruiting
NCT02875548 2025-11-04
TRuST
Ipsen
Phase 1/2 Completed
NCT06277154 2025-07-24
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
HRYZ Biotech Co.
Phase 2 Recruiting
NCT06644755 2025-07-24
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
Daiichi Sankyo
Phase 1 Recruiting
NCT02601950 2025-06-22
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma
Ipsen
Phase 2 Completed
NCT04965753 2025-03-04
FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors
Foghorn Therapeutics Inc.
Phase 1 Terminated
NCT04537715 2025-02-19
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
Ipsen
Phase 1 Completed
NCT06748872 2024-12-27
EPITOME-1015-I
Medigene AG
Phase 1 Not yet recruiting
NCT05355753 2024-12-17
A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors
C4 Therapeutics, Inc.
Phase 1 Terminated
NCT03250325 2024-11-20
Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial Sarcoma
Takara Bio Inc.
Phase 1/2 Completed
NCT02601937 2024-10-03
EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Ipsen
Phase 1 Completed
NCT03604783 2024-09-19
Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors
Sumitomo Pharma America, Inc.
Phase 1 Terminated
NCT04176016 2024-02-02
Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory Synovial Sarcoma
OncoTherapy Science, Inc.
Phase 1 Terminated
NCT04145700 2023-09-13
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma
Eli Lilly and Company
Phase 1/2 Terminated
NCT00543712 2022-12-13
A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)
Genentech, Inc.
Phase 2 Terminated
NCT02609984 2020-07-07
IMDZ-C232
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Terminated
NCT03520959 2020-04-16
A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3 Terminated
NCT03638206 2019-12-11
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Shenzhen BinDeBio Ltd.
Phase 1/2 Unknown
NCT03697824 2019-10-29
Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a
GlaxoSmithKline
Phase 2 Withdrawn
NCT00668148 2018-07-17
A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma
Eli Lilly and Company
Phase 2 Completed
NCT00154388 2016-11-18
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
Phase 2 Completed
NCT00297258 2016-02-03
Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma
GlaxoSmithKline
Phase 2 Completed
NCT00503295 2014-10-02
Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung
Oncolytics Biotech
Phase 2 Completed
NCT00064220 2012-05-16
Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
Daiichi Sankyo
Phase 2 Completed